Who is sponsoring NCT03975504?

NCT03975504 is sponsored by Shanghai Chest Hospital.

What drugs are being tested in NCT03975504?

Interventions in NCT03975504: Low Dose Computed Tomography, artificial intelligence (AI), autofluorescence imaging (AFI).

What condition does NCT03975504 study?

NCT03975504 studies Lung Neoplasms.

Is NCT03975504 still recruiting?

NCT03975504 is currently status unknown. Last updated 1 June 2022.

Last reviewed 2022-06-01 · How we verify

NCT03975504

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

China Lung Cancer Screening (CLUS) Study Version 2.0

Status unknown NA Last updated 1 June 2022

What this trial tests

NA trial testing Low Dose Computed Tomography in Lung Neoplasms in 6,000 participants. Status unknown.

Timeline

1 August 2018

Primary endpoint
30 June 2023

31 July 2023

Quick facts

Lead sponsor	Shanghai Chest Hospital
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	screening
Enrollment	6,000
Start date	1 August 2018
Primary completion	30 June 2023
Estimated completion	31 July 2023
Sites	1 location across China

Drugs / interventions tested

Low Dose Computed Tomography
artificial intelligence (AI)
autofluorescence imaging (AFI)

Conditions studied

Lung Neoplasms — all drugs for Lung Neoplasms →

Sponsor

Shanghai Chest Hospital

Who can join

Adults 45 to 75, any sex, with Lung Neoplasms. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Our previous study, china lung cancer screening study version 1.0, had proven that LDCT led to a 74.1% increase in detecting early-stage lung cancer compare to usual care (NCT02898441). The present one arm study is performed to evaluate the efficacy of new techniques in improving the implementation of lung cancer screening and validate our previous findings. 6000 high-risk subjects (age 45-75) were recruited to take LDCT screening. (Baseline + 2 biennial repeated LDCT screening). Follow-up for lung cancer incidence, lung cancer mortality and overall mortality was performed. Blood samples were stored in a Biobank. Management of positive screening test was carried out by a pre-specified protocol.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Exploring the Potential of Non-Coding RNAs as Liquid Biopsy Biomarkers for Lung Cancer Screening: A Literature Review.
Garbo E, Del Rio B, Ferrari G, Cani M, et al · · 2023 · cited 11× · PMID 37835468 · DOI 10.3390/cancers15194774
Multimodal fusion of liquid biopsy and CT enhances differential diagnosis of early-stage lung adenocarcinoma.
Zhang Y, Sun B, Yu Y, Lu J, et al · · 2024 · cited 10× · PMID 38409480 · DOI 10.1038/s41698-024-00551-8
Focus on lung cancer screening.
Tartarone A, Lerose R, Aieta M. · · 2020 · cited 8× · PMID 32802463 · DOI 10.21037/jtd.2020.02.17

Verify or expand the search:

Other recruiting trials for Lung Neoplasms

Currently open trials in the same condition.

NCT07476287 — Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult · Phase 2 · recruiting
NCT07509333 — MDT-Based Umbrella Decision Model for Geriatric Lung Cancer Patients · NA · recruiting
NCT07109154 — DeniLA: Comprehensive Demographics and Clinical Profile of NSCLC Patients: Analyzing Guideline-Concordant Care in First- · recruiting
NCT06974604 — Preventing Dato-DXd Associated Stomatitis With Dexamethasone Mouthwash, TROPION-DM · Phase 2 · recruiting
NCT07165691 — TELEhealth Shared Decision-making COaching for Lung Cancer Screening in Primary Care (TELESCOPE) for Hispanics · NA · recruiting

Other Shanghai Chest Hospital trials

Trials by the same sponsor.

NCT07515027 — Electroacupuncture Plus 5-HT3 Receptor Inhibitor for PONV Prevention in High-Risk Patients Undergoing Thoracoscopic Lung · NA · recruiting
NCT07479628 — Neoadjuvant Adebrelimab Plus CRT for Locally Advanced Thymic Carcinoma · Phase 2 · not yet recruiting
NCT07528066 — Downstaging and RATS After Neo-Chemo-IO: Impact on Surgical Outcomes in NSCLC · recruiting
NCT07331727 — Epicardial Adipose Tissue-Targeted DApagliflozin for Reducing Electrical Remodeling in Atrial Fibrillation · NA · not yet recruiting
NCT07320768 — Renal Denervation Combined With Pulsed Field Ablation to Prevent Blanking-Period Recurrence in Persistent Atrial Fibrill · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03975504 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai Chest Hospital
Last refreshed: 1 June 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03975504.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing